Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stroke | 104 | 2022 | 9757 | 6.450 |
Why?
|
Brain Ischemia | 56 | 2022 | 3049 | 6.290 |
Why?
|
Periodicals as Topic | 11 | 2020 | 1463 | 2.370 |
Why?
|
Thrombectomy | 10 | 2022 | 705 | 2.350 |
Why?
|
Tissue Plasminogen Activator | 20 | 2018 | 1164 | 2.210 |
Why?
|
Neuroprotective Agents | 17 | 2020 | 957 | 2.160 |
Why?
|
Endovascular Procedures | 11 | 2022 | 2183 | 2.090 |
Why?
|
Thrombolytic Therapy | 20 | 2020 | 2064 | 1.970 |
Why?
|
Fibrinolytic Agents | 19 | 2020 | 2084 | 1.920 |
Why?
|
Editorial Policies | 4 | 2017 | 458 | 1.550 |
Why?
|
Infarction, Middle Cerebral Artery | 11 | 2020 | 485 | 1.480 |
Why?
|
Clinical Trials as Topic | 27 | 2018 | 8002 | 1.460 |
Why?
|
Cerebrovascular Disorders | 7 | 2018 | 1474 | 1.200 |
Why?
|
Cerebrovascular Circulation | 14 | 2019 | 2727 | 1.180 |
Why?
|
Reperfusion | 7 | 2022 | 271 | 0.920 |
Why?
|
Health Planning Guidelines | 4 | 2009 | 151 | 0.790 |
Why?
|
Diffusion Magnetic Resonance Imaging | 13 | 2019 | 2790 | 0.760 |
Why?
|
Atrial Fibrillation | 7 | 2020 | 5127 | 0.740 |
Why?
|
Intracranial Embolism | 4 | 2014 | 189 | 0.740 |
Why?
|
Review Literature as Topic | 2 | 2017 | 348 | 0.740 |
Why?
|
Ischemic Attack, Transient | 7 | 2020 | 882 | 0.710 |
Why?
|
Neurology | 6 | 2021 | 780 | 0.670 |
Why?
|
Academies and Institutes | 1 | 2021 | 318 | 0.640 |
Why?
|
Reperfusion Injury | 5 | 2016 | 1023 | 0.630 |
Why?
|
Research | 5 | 2020 | 1982 | 0.590 |
Why?
|
Foramen Ovale, Patent | 2 | 2018 | 208 | 0.570 |
Why?
|
Arterial Occlusive Diseases | 1 | 2021 | 748 | 0.560 |
Why?
|
Evidence-Based Medicine | 4 | 2017 | 3688 | 0.540 |
Why?
|
Platelet Aggregation Inhibitors | 6 | 2017 | 2751 | 0.540 |
Why?
|
Anticoagulants | 8 | 2020 | 4812 | 0.520 |
Why?
|
International Cooperation | 3 | 2019 | 1422 | 0.510 |
Why?
|
Drug Design | 3 | 2010 | 1048 | 0.470 |
Why?
|
Disease Models, Animal | 18 | 2020 | 18252 | 0.470 |
Why?
|
Research Design | 8 | 2017 | 6180 | 0.460 |
Why?
|
Granulocyte Colony-Stimulating Factor | 3 | 2013 | 629 | 0.450 |
Why?
|
Intracranial Hemorrhages | 3 | 2018 | 822 | 0.440 |
Why?
|
Interdisciplinary Communication | 2 | 2020 | 931 | 0.420 |
Why?
|
Brain Infarction | 3 | 2013 | 290 | 0.420 |
Why?
|
Publishing | 1 | 2020 | 833 | 0.420 |
Why?
|
Biomedical Research | 6 | 2019 | 3429 | 0.390 |
Why?
|
Magnetic Resonance Angiography | 4 | 2014 | 1432 | 0.390 |
Why?
|
Humans | 109 | 2022 | 761504 | 0.390 |
Why?
|
Cooperative Behavior | 3 | 2018 | 1505 | 0.390 |
Why?
|
Treatment Outcome | 29 | 2022 | 64680 | 0.380 |
Why?
|
Patient Selection | 9 | 2018 | 4244 | 0.370 |
Why?
|
Freezing | 1 | 2011 | 311 | 0.360 |
Why?
|
Intracranial Thrombosis | 1 | 2011 | 108 | 0.340 |
Why?
|
Ticlopidine | 2 | 2006 | 730 | 0.340 |
Why?
|
Cerebral Infarction | 4 | 2012 | 983 | 0.340 |
Why?
|
Cytoprotection | 2 | 2022 | 200 | 0.340 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2017 | 3245 | 0.340 |
Why?
|
Rats | 18 | 2017 | 23742 | 0.330 |
Why?
|
Decision Support Techniques | 1 | 2019 | 1998 | 0.330 |
Why?
|
Time Factors | 23 | 2019 | 39967 | 0.330 |
Why?
|
Benzenesulfonates | 2 | 2006 | 166 | 0.320 |
Why?
|
Acute Disease | 13 | 2010 | 7237 | 0.310 |
Why?
|
Laser-Doppler Flowmetry | 1 | 2008 | 239 | 0.310 |
Why?
|
Self-Evaluation Programs | 1 | 2007 | 29 | 0.300 |
Why?
|
Thrombophilia | 1 | 2010 | 305 | 0.300 |
Why?
|
Embolism | 2 | 2008 | 399 | 0.290 |
Why?
|
Warfarin | 3 | 2020 | 1483 | 0.290 |
Why?
|
Circle of Willis | 1 | 2007 | 78 | 0.290 |
Why?
|
Disability Evaluation | 2 | 2019 | 1835 | 0.270 |
Why?
|
Cardiology | 1 | 2018 | 1656 | 0.270 |
Why?
|
Patient Care Team | 1 | 2018 | 2521 | 0.270 |
Why?
|
Nitrogen Oxides | 1 | 2006 | 129 | 0.270 |
Why?
|
Hyperoxia | 1 | 2008 | 258 | 0.270 |
Why?
|
Rats, Sprague-Dawley | 11 | 2009 | 8181 | 0.270 |
Why?
|
Animals | 40 | 2021 | 168459 | 0.260 |
Why?
|
Rats, Wistar | 5 | 2020 | 1848 | 0.260 |
Why?
|
Patient-Centered Care | 1 | 2016 | 1421 | 0.260 |
Why?
|
Free Radical Scavengers | 1 | 2006 | 211 | 0.250 |
Why?
|
Brain | 8 | 2022 | 27112 | 0.250 |
Why?
|
Organizations | 2 | 2021 | 171 | 0.240 |
Why?
|
Middle Cerebral Artery | 1 | 2006 | 275 | 0.240 |
Why?
|
Cerebral Arteries | 1 | 2007 | 490 | 0.230 |
Why?
|
Gadolinium | 1 | 2009 | 960 | 0.230 |
Why?
|
Biomedical Technology | 1 | 2007 | 211 | 0.230 |
Why?
|
Secondary Prevention | 5 | 2018 | 1475 | 0.230 |
Why?
|
Randomized Controlled Trials as Topic | 9 | 2018 | 10209 | 0.230 |
Why?
|
Nerve Fibers | 1 | 2007 | 708 | 0.220 |
Why?
|
China | 3 | 2020 | 2369 | 0.220 |
Why?
|
Therapeutics | 1 | 2004 | 113 | 0.220 |
Why?
|
Magnetic Resonance Imaging | 13 | 2020 | 36426 | 0.220 |
Why?
|
Plaque, Atherosclerotic | 1 | 2015 | 1533 | 0.210 |
Why?
|
Device Approval | 1 | 2005 | 163 | 0.210 |
Why?
|
Choice Behavior | 1 | 2008 | 824 | 0.200 |
Why?
|
Myocardial Infarction | 3 | 2018 | 11460 | 0.190 |
Why?
|
Recombinant Proteins | 5 | 2016 | 6534 | 0.190 |
Why?
|
Tomography, X-Ray Computed | 5 | 2020 | 20570 | 0.190 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2011 | 2872 | 0.190 |
Why?
|
Hypothermia | 1 | 2003 | 188 | 0.190 |
Why?
|
Recovery of Function | 4 | 2019 | 2979 | 0.180 |
Why?
|
Cardiovascular Diseases | 3 | 2019 | 15500 | 0.180 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2002 | 344 | 0.180 |
Why?
|
Basilar Artery | 1 | 2021 | 205 | 0.180 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2005 | 1334 | 0.170 |
Why?
|
Microspheres | 1 | 2003 | 784 | 0.170 |
Why?
|
Aspirin | 2 | 2009 | 3133 | 0.170 |
Why?
|
Cerebral Hemorrhage | 3 | 2005 | 2656 | 0.160 |
Why?
|
Hemorrhage | 5 | 2019 | 3424 | 0.150 |
Why?
|
Drug Therapy, Combination | 5 | 2011 | 6310 | 0.150 |
Why?
|
Perfusion Imaging | 1 | 2019 | 196 | 0.150 |
Why?
|
Caspase 3 | 1 | 2020 | 731 | 0.150 |
Why?
|
Quality Assurance, Health Care | 1 | 2007 | 2169 | 0.140 |
Why?
|
Male | 39 | 2019 | 360804 | 0.140 |
Why?
|
Ischemic Preconditioning | 1 | 2017 | 89 | 0.140 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2010 | 4016 | 0.140 |
Why?
|
Homes for the Aged | 1 | 2019 | 272 | 0.140 |
Why?
|
Protein C | 1 | 2016 | 133 | 0.130 |
Why?
|
Medulla Oblongata | 1 | 2017 | 248 | 0.130 |
Why?
|
Contrast Media | 1 | 2009 | 5311 | 0.130 |
Why?
|
Disease Management | 2 | 2005 | 2508 | 0.130 |
Why?
|
Forecasting | 2 | 2015 | 2928 | 0.130 |
Why?
|
History, 21st Century | 2 | 2020 | 1567 | 0.130 |
Why?
|
Injections, Intravenous | 3 | 2009 | 1379 | 0.120 |
Why?
|
Telemedicine | 4 | 2020 | 3051 | 0.120 |
Why?
|
Histone Deacetylases | 1 | 2020 | 719 | 0.120 |
Why?
|
Heparin | 1 | 2002 | 1634 | 0.120 |
Why?
|
Endpoint Determination | 2 | 2008 | 590 | 0.120 |
Why?
|
Nursing Homes | 2 | 2020 | 1082 | 0.120 |
Why?
|
Stem Cell Transplantation | 1 | 2003 | 1600 | 0.120 |
Why?
|
Ibuprofen | 1 | 2016 | 229 | 0.120 |
Why?
|
Membrane Proteins | 1 | 2011 | 7856 | 0.120 |
Why?
|
Attitude of Health Personnel | 1 | 2008 | 3889 | 0.120 |
Why?
|
Astrocytes | 1 | 2002 | 1346 | 0.110 |
Why?
|
Risk Assessment | 5 | 2019 | 23995 | 0.110 |
Why?
|
Drug Approval | 3 | 2005 | 814 | 0.110 |
Why?
|
Risk Factors | 9 | 2019 | 74206 | 0.110 |
Why?
|
Diffusion | 2 | 2008 | 814 | 0.110 |
Why?
|
Acupuncture Therapy | 1 | 2017 | 486 | 0.110 |
Why?
|
Clinical Laboratory Techniques | 2 | 2020 | 746 | 0.110 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2016 | 370 | 0.100 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2019 | 1222 | 0.100 |
Why?
|
Radiography | 3 | 2015 | 6965 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3084 | 0.100 |
Why?
|
Tetrazolium Salts | 2 | 2009 | 93 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3204 | 0.100 |
Why?
|
Vascular Surgical Procedures | 2 | 2013 | 1489 | 0.100 |
Why?
|
Acetaminophen | 1 | 2016 | 554 | 0.100 |
Why?
|
Primary Prevention | 2 | 2018 | 1186 | 0.100 |
Why?
|
Protein S Deficiency | 1 | 2010 | 13 | 0.090 |
Why?
|
Annexin A2 | 1 | 2011 | 44 | 0.090 |
Why?
|
Protein C Deficiency | 1 | 2010 | 25 | 0.090 |
Why?
|
Blood Pressure | 4 | 2017 | 8481 | 0.090 |
Why?
|
Factor V Deficiency | 1 | 2010 | 10 | 0.090 |
Why?
|
Diffusion of Innovation | 1 | 2016 | 728 | 0.090 |
Why?
|
Antithrombin III Deficiency | 1 | 2010 | 28 | 0.090 |
Why?
|
Registries | 3 | 2019 | 8224 | 0.090 |
Why?
|
Clinical Protocols | 1 | 2016 | 1440 | 0.090 |
Why?
|
Perfusion | 2 | 2013 | 1373 | 0.090 |
Why?
|
Sensation Disorders | 2 | 2012 | 160 | 0.090 |
Why?
|
Pandemics | 2 | 2020 | 8654 | 0.090 |
Why?
|
Fibrinolysis | 1 | 2011 | 332 | 0.080 |
Why?
|
Infrared Rays | 2 | 2009 | 247 | 0.080 |
Why?
|
Health Services Needs and Demand | 1 | 2017 | 1403 | 0.080 |
Why?
|
Rats, Inbred WKY | 3 | 2017 | 151 | 0.080 |
Why?
|
Aged, 80 and over | 11 | 2020 | 58976 | 0.080 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2008 | 1516 | 0.080 |
Why?
|
Neurons | 3 | 2011 | 9463 | 0.080 |
Why?
|
Cerebral Cortex | 1 | 2005 | 5777 | 0.080 |
Why?
|
Magnetic Field Therapy | 1 | 2008 | 27 | 0.080 |
Why?
|
Checklist | 1 | 2015 | 827 | 0.080 |
Why?
|
Cell Death | 2 | 2011 | 1678 | 0.080 |
Why?
|
Diagnostic Imaging | 3 | 2008 | 3530 | 0.080 |
Why?
|
Aged | 18 | 2020 | 169289 | 0.080 |
Why?
|
Infusions, Intra-Arterial | 1 | 2008 | 221 | 0.080 |
Why?
|
Fibrin | 1 | 2011 | 507 | 0.080 |
Why?
|
Neuroradiography | 1 | 2008 | 71 | 0.080 |
Why?
|
Hospital Units | 1 | 2009 | 142 | 0.070 |
Why?
|
Predictive Value of Tests | 3 | 2019 | 15266 | 0.070 |
Why?
|
Catheters | 1 | 2011 | 427 | 0.070 |
Why?
|
Data Interpretation, Statistical | 2 | 2008 | 2691 | 0.070 |
Why?
|
Ganglia, Parasympathetic | 1 | 2007 | 18 | 0.070 |
Why?
|
Cerebral Angiography | 2 | 2014 | 1281 | 0.070 |
Why?
|
Reproducibility of Results | 3 | 2019 | 20098 | 0.070 |
Why?
|
United States | 11 | 2020 | 72334 | 0.070 |
Why?
|
Fibrinogen | 1 | 2011 | 888 | 0.070 |
Why?
|
Health Priorities | 1 | 2010 | 374 | 0.070 |
Why?
|
Hemodynamics | 1 | 2017 | 4159 | 0.070 |
Why?
|
Virginia | 1 | 2007 | 116 | 0.070 |
Why?
|
Software | 2 | 2019 | 4434 | 0.070 |
Why?
|
Health Care Sector | 1 | 2009 | 195 | 0.070 |
Why?
|
Severity of Illness Index | 5 | 2009 | 15842 | 0.070 |
Why?
|
Myocardial Reperfusion | 1 | 2008 | 338 | 0.070 |
Why?
|
National Health Programs | 1 | 2010 | 440 | 0.070 |
Why?
|
Oxidative Stress | 1 | 2017 | 3113 | 0.070 |
Why?
|
Hospitals, University | 1 | 2008 | 563 | 0.070 |
Why?
|
Middle Aged | 16 | 2019 | 220895 | 0.070 |
Why?
|
Female | 21 | 2019 | 392644 | 0.070 |
Why?
|
Hypertension | 3 | 2017 | 8540 | 0.060 |
Why?
|
Guidelines as Topic | 2 | 2010 | 1386 | 0.060 |
Why?
|
Cortical Spreading Depression | 1 | 2009 | 288 | 0.060 |
Why?
|
Practice Guidelines as Topic | 2 | 2014 | 7390 | 0.060 |
Why?
|
Regional Blood Flow | 1 | 2008 | 1496 | 0.060 |
Why?
|
Education, Medical, Continuing | 1 | 2010 | 823 | 0.060 |
Why?
|
World Health Organization | 2 | 2013 | 1322 | 0.060 |
Why?
|
Language | 1 | 2014 | 1540 | 0.060 |
Why?
|
Species Specificity | 1 | 2009 | 2414 | 0.060 |
Why?
|
Double-Blind Method | 4 | 2017 | 12341 | 0.060 |
Why?
|
Odds Ratio | 2 | 2007 | 9646 | 0.060 |
Why?
|
Peer Review, Research | 1 | 2007 | 340 | 0.060 |
Why?
|
Emergency Medical Services | 3 | 2020 | 1923 | 0.060 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2007 | 793 | 0.060 |
Why?
|
Equipment Safety | 1 | 2005 | 249 | 0.060 |
Why?
|
Stents | 1 | 2016 | 3179 | 0.060 |
Why?
|
Dipyridamole | 1 | 2003 | 140 | 0.060 |
Why?
|
Infusions, Intravenous | 1 | 2008 | 2219 | 0.060 |
Why?
|
Databases, Factual | 2 | 2010 | 7967 | 0.050 |
Why?
|
Aorta | 1 | 2011 | 2042 | 0.050 |
Why?
|
Sample Size | 1 | 2006 | 841 | 0.050 |
Why?
|
Drug Administration Schedule | 2 | 2008 | 4853 | 0.050 |
Why?
|
Comprehension | 1 | 2008 | 621 | 0.050 |
Why?
|
Legislation, Drug | 1 | 2005 | 214 | 0.050 |
Why?
|
Health Services Research | 1 | 2010 | 1812 | 0.050 |
Why?
|
Movement Disorders | 1 | 2006 | 459 | 0.050 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2006 | 857 | 0.050 |
Why?
|
Risk | 2 | 2005 | 9610 | 0.050 |
Why?
|
Europe | 1 | 2009 | 3422 | 0.050 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2008 | 1241 | 0.050 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5336 | 0.050 |
Why?
|
Heptanoic Acids | 1 | 2004 | 344 | 0.050 |
Why?
|
Brain Injuries | 1 | 2013 | 2053 | 0.050 |
Why?
|
Boronic Acids | 1 | 2006 | 915 | 0.050 |
Why?
|
Nervous System Diseases | 1 | 2012 | 1666 | 0.050 |
Why?
|
Administration, Oral | 2 | 2020 | 4021 | 0.050 |
Why?
|
Simvastatin | 1 | 2004 | 346 | 0.050 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2009 | 9000 | 0.050 |
Why?
|
Recurrence | 3 | 2016 | 8465 | 0.050 |
Why?
|
Carbon Dioxide | 1 | 2005 | 1147 | 0.050 |
Why?
|
Retrospective Studies | 5 | 2020 | 80636 | 0.040 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2005 | 2496 | 0.040 |
Why?
|
Equipment Design | 1 | 2008 | 3510 | 0.040 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2005 | 452 | 0.040 |
Why?
|
Pyrazines | 1 | 2006 | 1201 | 0.040 |
Why?
|
Patient Education as Topic | 1 | 2010 | 2319 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 2017 | 5440 | 0.040 |
Why?
|
Internet | 2 | 2010 | 3092 | 0.040 |
Why?
|
Cognition Disorders | 1 | 2013 | 3979 | 0.040 |
Why?
|
Internationality | 2 | 2020 | 1001 | 0.040 |
Why?
|
Regression Analysis | 2 | 2008 | 6343 | 0.040 |
Why?
|
Peptides | 1 | 2011 | 4358 | 0.040 |
Why?
|
Politics | 1 | 2006 | 815 | 0.040 |
Why?
|
Models, Animal | 1 | 2005 | 2112 | 0.040 |
Why?
|
Drug Industry | 1 | 2005 | 788 | 0.040 |
Why?
|
Drug Synergism | 1 | 2003 | 1755 | 0.040 |
Why?
|
Microscopy, Electron | 1 | 2002 | 2561 | 0.040 |
Why?
|
Behavior, Animal | 1 | 2006 | 1878 | 0.040 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2019 | 168 | 0.040 |
Why?
|
Activities of Daily Living | 1 | 2007 | 2421 | 0.040 |
Why?
|
Health Care Surveys | 2 | 2019 | 2426 | 0.040 |
Why?
|
Multivariate Analysis | 2 | 2017 | 12059 | 0.040 |
Why?
|
Suture Techniques | 1 | 2003 | 769 | 0.040 |
Why?
|
Videoconferencing | 1 | 2020 | 203 | 0.040 |
Why?
|
Rats, Inbred SHR | 1 | 2017 | 186 | 0.040 |
Why?
|
Collateral Circulation | 1 | 2019 | 294 | 0.040 |
Why?
|
Hypothalamus | 1 | 2003 | 999 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2010 | 5492 | 0.040 |
Why?
|
Pyrroles | 1 | 2004 | 1125 | 0.040 |
Why?
|
Drug Combinations | 1 | 2003 | 2048 | 0.040 |
Why?
|
Image Enhancement | 1 | 2008 | 2885 | 0.040 |
Why?
|
Automation | 1 | 2019 | 586 | 0.030 |
Why?
|
Medicare | 3 | 2020 | 6770 | 0.030 |
Why?
|
Urbanization | 1 | 2017 | 100 | 0.030 |
Why?
|
Treatment Failure | 1 | 2003 | 2645 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2005 | 1089 | 0.030 |
Why?
|
Drug Substitution | 1 | 2019 | 290 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2005 | 1664 | 0.030 |
Why?
|
Blood Glucose | 1 | 2010 | 6391 | 0.030 |
Why?
|
Electrocardiography | 1 | 2009 | 6377 | 0.030 |
Why?
|
Teaching Rounds | 1 | 2020 | 275 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2011 | 18965 | 0.030 |
Why?
|
Reference Values | 1 | 2003 | 4920 | 0.030 |
Why?
|
Water | 1 | 2002 | 1411 | 0.030 |
Why?
|
Antihypertensive Agents | 1 | 2004 | 2024 | 0.030 |
Why?
|
Sympathetic Nervous System | 1 | 2017 | 518 | 0.030 |
Why?
|
Reimbursement Mechanisms | 1 | 2020 | 667 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2020 | 1668 | 0.030 |
Why?
|
Skilled Nursing Facilities | 1 | 2018 | 398 | 0.030 |
Why?
|
Disaster Planning | 1 | 2020 | 557 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2014 | 14666 | 0.030 |
Why?
|
Injections, Intra-Arterial | 1 | 2014 | 182 | 0.030 |
Why?
|
Nursing Staff, Hospital | 1 | 2017 | 348 | 0.030 |
Why?
|
Intracranial Aneurysm | 1 | 2004 | 1285 | 0.030 |
Why?
|
Health Resources | 1 | 2020 | 935 | 0.030 |
Why?
|
Filgrastim | 1 | 2013 | 132 | 0.030 |
Why?
|
Oxygen | 1 | 2005 | 4227 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2018 | 12463 | 0.030 |
Why?
|
Cross-Sectional Studies | 2 | 2019 | 26125 | 0.030 |
Why?
|
Drug Utilization | 1 | 2019 | 1188 | 0.030 |
Why?
|
Patient Transfer | 1 | 2020 | 794 | 0.030 |
Why?
|
Prognosis | 3 | 2010 | 29625 | 0.030 |
Why?
|
Patient Admission | 1 | 2020 | 1367 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2010 | 22176 | 0.030 |
Why?
|
Postoperative Care | 1 | 2019 | 1468 | 0.030 |
Why?
|
Horner Syndrome | 1 | 2012 | 36 | 0.030 |
Why?
|
Thromboembolism | 1 | 2018 | 995 | 0.020 |
Why?
|
Cardiac Surgical Procedures | 1 | 2007 | 3627 | 0.020 |
Why?
|
Hemiplegia | 1 | 2012 | 136 | 0.020 |
Why?
|
Thrombosis | 1 | 2006 | 2942 | 0.020 |
Why?
|
Brain Mapping | 1 | 2007 | 6630 | 0.020 |
Why?
|
Fear | 1 | 2020 | 1476 | 0.020 |
Why?
|
Prospective Studies | 3 | 2017 | 54425 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2003 | 8529 | 0.020 |
Why?
|
Ophthalmoplegia | 1 | 2012 | 168 | 0.020 |
Why?
|
Cohort Studies | 3 | 2020 | 41487 | 0.020 |
Why?
|
Paralysis | 1 | 2012 | 250 | 0.020 |
Why?
|
Hemianopsia | 1 | 2012 | 121 | 0.020 |
Why?
|
Decision Making | 1 | 2004 | 3929 | 0.020 |
Why?
|
Glasgow Coma Scale | 1 | 2012 | 580 | 0.020 |
Why?
|
Adult | 7 | 2019 | 221177 | 0.020 |
Why?
|
Preoperative Care | 1 | 2019 | 2242 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2017 | 2141 | 0.020 |
Why?
|
Antioxidants | 1 | 2017 | 1668 | 0.020 |
Why?
|
Area Under Curve | 1 | 2013 | 1638 | 0.020 |
Why?
|
American Heart Association | 1 | 2014 | 1039 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2020 | 2775 | 0.020 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2009 | 186 | 0.020 |
Why?
|
Organizational Objectives | 1 | 2010 | 426 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2020 | 3575 | 0.020 |
Why?
|
Health Promotion | 1 | 2020 | 2214 | 0.020 |
Why?
|
Technology | 1 | 2010 | 292 | 0.020 |
Why?
|
Validation Studies as Topic | 1 | 2008 | 162 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2011 | 1572 | 0.020 |
Why?
|
Linear Models | 1 | 2017 | 5871 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2017 | 6814 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6484 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2020 | 3205 | 0.020 |
Why?
|
Databases as Topic | 1 | 2008 | 473 | 0.020 |
Why?
|
Quality of Life | 1 | 2007 | 13367 | 0.020 |
Why?
|
Catheterization | 1 | 2011 | 1428 | 0.020 |
Why?
|
Brain Damage, Chronic | 1 | 2006 | 267 | 0.020 |
Why?
|
Streptokinase | 1 | 2005 | 186 | 0.020 |
Why?
|
Hypercapnia | 1 | 2006 | 261 | 0.020 |
Why?
|
Perceptual Disorders | 1 | 2006 | 198 | 0.010 |
Why?
|
Mice | 1 | 2011 | 81525 | 0.010 |
Why?
|
Health Education | 1 | 2010 | 1052 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2005 | 39106 | 0.010 |
Why?
|
Expert Testimony | 1 | 2005 | 364 | 0.010 |
Why?
|
History, 20th Century | 1 | 2010 | 2767 | 0.010 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2005 | 577 | 0.010 |
Why?
|
Societies, Medical | 1 | 2014 | 3905 | 0.010 |
Why?
|
Benchmarking | 1 | 2008 | 1045 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2008 | 2707 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2013 | 7045 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2020 | 7879 | 0.010 |
Why?
|
Reaction Time | 1 | 2006 | 2082 | 0.010 |
Why?
|
Meta-Analysis as Topic | 1 | 2005 | 1380 | 0.010 |
Why?
|
Internship and Residency | 1 | 2020 | 5880 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2008 | 2220 | 0.010 |
Why?
|
Health Policy | 1 | 2010 | 2684 | 0.010 |
Why?
|
Public Health | 1 | 2010 | 2669 | 0.010 |
Why?
|
Phenotype | 1 | 2013 | 16591 | 0.010 |
Why?
|
Signal Transduction | 1 | 2017 | 23445 | 0.010 |
Why?
|
Hospital Mortality | 1 | 2008 | 5294 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2004 | 10766 | 0.010 |
Why?
|
Survival Analysis | 1 | 2004 | 10090 | 0.010 |
Why?
|
Young Adult | 1 | 2012 | 59243 | 0.000 |
Why?
|
Adolescent | 1 | 2013 | 88319 | 0.000 |
Why?
|